Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients
Status:
Unknown status
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The major clinical problems in patients with Marfan Syndrome (MFS) are aortic root dilation
(ARD), dissection and rupture. Although the available treatments (beta-blockers, BBs) improve
the evolution of the disease, they do not protect MFS patients from progression of ARD and
dissection. A key molecule that negatively influences cell growth, differentiation, survival
and death in MFS is TGFb which is antagonised by existing drugs employed in the clinical
practice, the Angiotensin II receptor blockers (ARB).